Investor Presentaiton

Strong Execution and Major Accomplishments in 2020 and YTD 2021 3.84bn 1-4 4 6 4 5 7 4 6 Commercial portfolio NDA approvals 2020 total revenue: RMB 3.84bn (product revenue RMB 2.37bn) TYVYTⓇ - (1L nsqNSCLC¹) BYVASDAⓇ • SULINNOⓇ 4 products - TYVYTⓇ - BYVASDAⓇ - SULINNOⓇ HALPRYZA® • • HALPRYZAⓇ • • NDA accepted Pivotal trial data release Late-stage assets New molecules Overseas out-licensing into IND deals TYVYTⓇ • TYVYTⓇ • IBI-310 (CTLA-4) • IBI-322 (PD-L1/CD47) ⚫ Eli Lilly Assets under global development TYVYTⓇ (PD-1) - (1L nsqNSCLC) - (1L nsqNSCLC) (TYVYT®) • IBI-306 (PCSK9) IBI-939 (TIGIT) - (1L sq NSCLC) (1L sq NSCLC) • Coherus (1L HCC) 1 - (2L sq NSCLC) IBI-375 (FGFR) • (1L HCC) (2L ESCC) TYVYTⓇ+BYVASDAⓇ IBI-376 (PI3KS) IBI-362 (OXM3) ⚫ IBI-375 (FGFR) • IBI-112 (IL-23) . Roche - (2L MCCA, Taiwan) IBI-326 (BCMA- CART) • IBI-319 (PD-1/4-1BB) (BYVASDAⓇ) (Bispecific, Cell therapy) ⚫ IBI-322 (PD-L1/CD47) ⚫ IBI-939 (TIGIT) . BYVASDAⓇ (VEGF) • IBI-188 (CD47) BYVASDA • IBI-323 (PD-L1/LAG3) • IBI-110 (LAG-3) • - (1L HCC)1 • IBI-102 (GITR) PT Etana¹ (BYVASDAⓇ) • Innovent Academy Dr. Yong Jun Liu joined as President Organization • US Lab in setup • Over 3,600 employees Capacity • Production line in operation expanded from 5,000L to 24,000L Additional 36,000L stainless production line in construction Note: 1. 1L nsq NSCLC of TYVYT was approved in Feb 2021. 1L HCC's and 2L sq NSCLC's NDA acceptance in Jan 2021; Collaboration with PT Etana in Jan 2021 Confidential Copyright©2021 Innovent Biologics Innovent

View entire presentation